CD274 and breast carcinoma: To establish the serum PD-L1 level as a biomarker, further validation studies are needed to compare the benefit of using laboratory-based tumor pathology with the serum levels of PD-L1 to select TNBC and other breast cancer patients for immune checkpoint inhibitor treatment options.